• Many investors are considering whether Albemarle's current share price fairly reflects its potential, or if the stock might be mispriced.
• The stock recently closed at US$177.47, with a 4.3% gain over the past 7 days, a decline of 11.1% over the past 30 days, and returns of 23.3% year to date and 211.1% over the last year.
• Recent headlines around Albemarle have kept attention on the stock, and investors are closely watching how broader sentiment toward materials and battery related companies affects pricing. This context helps explain why short term moves can look very different from the longer term performance profile.
• Albemarle currently scores 2 out of 6 on Simply Wall St's valuation checks, as shown in its valuation score. The next sections will walk through traditional valuation approaches before considering a more complete way to think about what that score really means.

Albemarle scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Albemarle Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those cash flows back to what they might be worth today.

For Albemarle, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow (FCF) is reported as a loss of $106 million. Analysts and internal estimates then project FCF turning positive and reaching $1,679 million by 2030. This uses a series of annual projections between 2026 and 2035 that are discounted back to today using the DCF framework.

On this basis, the DCF model points to an estimated intrinsic value of about $349.79 per share. Compared with the recent share price of $177.47, this implies the stock is about 49.3% below that DCF estimate. This indicates Albemarle screens as undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Albemarle is undervalued by 49.3%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Albemarle Price vs Sales

For companies where earnings can be volatile or temporarily low, the P/S ratio is often a useful cross check because it compares the stock price to revenue, which is usually more stable than profits.

What counts as a “normal” or “fair” P/S ratio tends to reflect how fast investors expect revenue to grow and how much risk they see in those cash flows. Higher expected growth or lower perceived risk is often linked to higher P/S multiples.

Albemarle currently trades on a P/S ratio of 3.81x. This sits above the Chemicals industry average of 1.14x and also above the peer group average of 2.68x, which on a simple comparison can make the stock look relatively expensive.

Simply Wall St’s Fair Ratio for Albemarle is 1.99x. This proprietary metric estimates the P/S multiple that might be reasonable after considering factors such as earnings growth, industry, profit margins, market cap and key risks, rather than relying only on broad industry or peer averages.

Because the Fair Ratio of 1.99x is meaningfully below the current P/S of 3.81x, Albemarle screens as overvalued on this sales based view.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Albemarle Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced as a simple way for you to tell a story about Albemarle and then connect that story to your own forecasts for revenue, earnings, margins and a Fair Value that can be compared directly with the current share price.

On Simply Wall St's Community page, Narratives are set up so you can see how a bullish Albemarle view that supports a Fair Value of US$264, with assumptions like earnings reaching US$2.7b and a P/E of 14.1x, contrasts with a far more cautious view that points to a Fair Value of US$58 with earnings of US$534.3m and a P/E of 16.2x. This helps you decide where your own expectations sit between those two stories.

Because Narratives on the platform are refreshed when new news, guidance or earnings are added, you can see how the story and the Fair Value behind it evolve over time, rather than relying only on static multiples that can quickly become outdated.

For Albemarle however we will make it really easy for you with previews of two leading Albemarle Narratives:

Fair Value: US$264.00

Gap to Fair Value: Albemarle trades about 32.8% below this fair value on this bullish view.

Revenue Growth Assumption: 15.8% per year

• Higher long term lithium demand, cost improvements and productivity gains are expected to support stronger margins and revenue than consensus.
• The narrative leans on Albemarle's existing low cost assets, expansion options and policy support to back a higher earnings base and a P/E of 14.1x by 2029.
• Key watchpoints include lithium price weakness, regulatory and geopolitical risk, potential underinvestment, new battery technologies and tighter ESG rules that could all pressure margins.

Fair Value: US$172.62

Gap to Fair Value: Albemarle trades about 2.8% above this fair value on this more cautious view.

Revenue Growth Assumption: 7.9% per year

• This view expects solid but more moderate revenue growth and margins as cost savings, long term contracts and policy support offset lithium price volatility.
• The analysts behind it work with a consensus target of US$85.47 that assumes earnings of US$1.1b by 2028 and a P/E of 11.9x, suggesting limited upside if those assumptions hold.
• Ongoing risks such as prolonged low lithium prices, oversupply, policy shifts, alternative chemistries and regulatory hurdles are central to why this narrative treats Albemarle as closer to fairly priced.

With these two narratives, you can quickly see whether your own expectations for lithium prices, Albemarle's execution and long term margins sit closer to the bullish or cautious end of the range, or somewhere in between.

Do you think there's more to the story for Albemarle? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.